Results 71 to 80 of about 212,261 (297)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma

open access: yesFrontiers in Endocrinology, 2023
The progression of non-alcoholic fatty liver disease (NAFLD), the most common liver disease, leads to non-alcoholic steatohepatitis and hepatocellular carcinoma.
Seogsong Jeong   +3 more
doaj   +1 more source

Effect of Insulin-Like Growth Factor-1 (IGF-1) on the expression of NFκB and cFLIP in Bovine Granulosa Cells [PDF]

open access: yes, 2014
Infertility, often attributed to follicular atresia, is a growing problem in the agricultural industry. Programmed cell death, also known as apoptosis, is a contributing factor of follicular atresia.
Docos, Samantha Kathleen
core   +1 more source

Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies

open access: yesAging Pathobiology and Therapeutics, 2021
Programmed cell death 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are important immune checkpoints, and their interactions can mediate immune suppression in the tumor microenvironment. Targeting PD-1 and PD-L1 are immune checkpoint inhibitors that bind to PD-1 and PD-L1, respectively, to block the signal pathway between the two and increase the
Wanying Zhao   +2 more
openaire   +2 more sources

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

open access: yes, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth   +2 more
core  

The convergence of radiation and immunogenic cell death signaling pathways. [PDF]

open access: yes, 2012
Ionizing radiation (IR) triggers programmed cell death in tumor cells through a variety of highly regulated processes. Radiation-induced tumor cell death has been studied extensively in vitro and is widely attributed to multiple distinct mechanisms ...
Barcellos-Hoff, Mary H   +4 more
core   +2 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

open access: yesMolecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni   +11 more
wiley   +1 more source

Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade

open access: yesCase Reports in Dermatology, 2020
Hypertrophic lichen planus (HLP) may not have the typical histological findings of lichen planus and often mimics squamous cell carcinoma (SCC). Distinguishing between the two can pose a diagnostic challenge.
Caitlyn N. Myrdal   +2 more
doaj   +1 more source

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

open access: yesMolecules, 2022
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex.
Shabnam Shaabani   +12 more
doaj   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy